Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
FAQ
- What is Prime Medicine's D&A?
- Prime Medicine (PRME) reported D&A of $1.79M in Q2 2026.
- How has Prime Medicine's D&A changed year-over-year?
- Prime Medicine's D&A decreased by 4.2% year-over-year, from $1.86M to $1.79M.
- What is the long-term trend for Prime Medicine's D&A?
- Over 3 years (2022 to 2025), Prime Medicine's D&A has grown at a 48.8% compound annual growth rate (CAGR), from $2.22M to $7.32M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Prime Medicine's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude